A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
Public ClinicalTrials.gov record NCT07232719. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3b Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
Study identification
- NCT ID
- NCT07232719
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 250 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 16, 2025
- Primary completion
- Jun 30, 2027
- Completion
- Jun 30, 2027
- Last update posted
- Apr 16, 2026
2025 – 2027
United States locations
- U.S. sites
- 19
- U.S. states
- 11
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Artemis Institute for Clinical Research | Riverside | California | 92503 | — |
| JEM Research Institute | Atlantis | Florida | 33462 | — |
| Headlands Research Orlando | Orlando | Florida | 32806 | — |
| Care Access - Tamarac | Tamarac | Florida | 33321 | — |
| Care Access - Arlington Heights | Arlington Heights | Illinois | 60005 | — |
| L-MARC Research Center | Louisville | Kentucky | 40213 | — |
| IMA Clinical Research Monroe - Armand | Monroe | Louisiana | 71201 | — |
| Pharmasite Research, Inc. | Baltimore | Maryland | 21208 | — |
| Clinical Research Professionals | Chesterfield | Missouri | 63005 | — |
| Clinvest Headlands Llc | Springfield | Missouri | 65807 | — |
| IMA Clinical Research Warren | Warren Township | New Jersey | 07059 | — |
| IMA Clinical Research Manhattan | New York | New York | 10036 | — |
| Trial Management Associates - Wilmington - Floral Parkway | Wilmington | North Carolina | 28403 | — |
| Cedar Health Research | Dallas | Texas | 75251 | — |
| Headlands Research-El Paso | El Paso | Texas | 79902 | — |
| Cedar Health Research - Euless | Euless | Texas | 76040 | — |
| Cedar Health Research - Fort Worth | Fort Worth | Texas | 76132 | — |
| Care Access - Houston | Houston | Texas | 77054 | — |
| IMA Clinical Research San Antonio | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
Recently updated Obesity trials
Other public records listing Obesity. Sorted by last update posted; newest first. Not a recommendation.
- NCT01143454: Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System Recruiting
- NCT07752979: Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities Recruiting
- NCT07792226: ENLIGHT Trial: ESG With Fundal Mucosal Ablation Not yet recruiting
- NCT07783802: A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event Not yet recruiting
- NCT07684144: Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) Recruiting
- NCT07554638: Incretin Therapies in Obesity-related HFpEF Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07232719, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2026 · Synced Jul 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07232719 live on ClinicalTrials.gov.